Cardiovascular Outcomes Data Transparency Vexes FDA, Sponsors
Executive Summary
FDA plans a public hearing Aug. 11 on confidentiality of interim results in cardiovascular outcomes safety trials, an issue that apparently has led to regulatory delays for Orexigen’s obesity treatment Contrave and Sanofi’s antidiabetic agent lixisenatide.